In our previous report, we demonstrated that either genetic deficiency of IFNγR signaling or pharmacologic inhibition of its downstream targets JAK1 and JAK2 using INCB018424 results in less GvHD after allo-HSCT by reducing alloreactive T cell trafficking to GvHD target organs [3]. The gene discussed is IFNGR1; the disease is graft versus host disease.